-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 MJ5kBb7Ihv0rL03U4xB1PH0ZzqJ0XuRUYrRijXXPhYtTqmLAPD3SyjogKG3bBJrU
 CueYnzOcm1ASGzGRM1mt4w==

<SEC-DOCUMENT>0000950123-10-020431.txt : 20100303
<SEC-HEADER>0000950123-10-020431.hdr.sgml : 20100303
<ACCEPTANCE-DATETIME>20100303132316
ACCESSION NUMBER:		0000950123-10-020431
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20100301
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20100303
DATE AS OF CHANGE:		20100303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GeoVax Labs, Inc.
		CENTRAL INDEX KEY:			0000832489
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				870455038
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52091
		FILM NUMBER:		10652539

	BUSINESS ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080
		BUSINESS PHONE:		678-384-7220

	MAIL ADDRESS:	
		STREET 1:		1900 LAKE PARK DRIVE
		STREET 2:		SUITE 380
		CITY:			SMYRNA
		STATE:			2Q
		ZIP:			30080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Geovax Labs, Inc.
		DATE OF NAME CHANGE:	20061002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DAUPHIN TECHNOLOGY INC
		DATE OF NAME CHANGE:	19940826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUCCESSO INC
		DATE OF NAME CHANGE:	19910410
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>g22351e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>WASHINGTON, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B><DIV style="width: 26%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of the<BR>
Securities Exchange Act of 1934</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of report (Date of earliest event reported): March&nbsp;1, 2010</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><DIV style="width: 26%; border-bottom: 1px solid #000000; font-size: 1px">&nbsp;</DIV></DIV>

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>GEOVAX LABS, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt"><B>(Exact name of registrant as specified in its charter)</B></DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware<BR>
(State or other jurisdiction of <BR>
incorporation or organization)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-52091<BR>
(Commission File No.)</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>87-0455038<BR>
(IRS Employee Identification No.)</B></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>1900 Lake Park Drive, Suite&nbsp;380<BR>
Smyrna, Georgia 30080<BR>
(Address of principal executive offices)</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>(678)&nbsp;384-7220<BR>
(Registrant&#146;s telephone number, including area code)</B></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy
the filing obligation of the Registrant under any of the following provisions (see General
Instruction A.2 below).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR240.14a-12)
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><FONT face="Wingdings">&#111;</FONT> Pre-commencement communications pursuant to Rule&nbsp;13e-4 &#169; under the Exchange Act (17 CFR 240.13(e)-4(c))
</DIV>


<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>







<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This Form 8-K and other reports filed by GeoVax Labs, Inc. (the &#147;registrant&#148;) from time
to time with the Securities and Exchange Commission (collectively the &#147;Filings&#148;) contain forward
looking statements and information that are based upon beliefs of, and information currently
available to, the registrant&#146;s management as well as estimates and assumptions made by the
registrant&#146;s management. When used in the Filings the words &#147;anticipate&#148;, &#147;believe&#148;, &#147;estimate&#148;,
&#147;expect&#148;, &#147;future&#148;, &#147;intend&#148;, &#147;plan&#148; or the negative if these terms and similar expressions as they
relate to the registrant or the registrant&#146;s management identify forward looking statements. Such
statements reflect the current view of the registrant with respect to future events and are subject
to risks, uncertainties, assumptions and other factors relating to the registrant&#146;s industry,
operations and results of operations and any businesses that may be acquired by the registrant.
Should one or more of these risks or uncertainties materialize, or should the underlying
assumptions prove incorrect, actual results may differ significantly from those anticipated,
believed, estimated, expected, intended or planned.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;1, 2010 we issued a press release reporting our results of operations for the quarter
and year ended December&nbsp;31, 2009. A copy of the press release is attached to this Current Report
as Exhibit&nbsp;99.1
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 Other Events</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On March&nbsp;1, 2010 we issued a press release announcing our intention to file a registration
statement for the sale of $20&nbsp;million or more of our common stock. A copy of the press release is
attached to this Current Report as Exhibit&nbsp;99.2
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.1 Press Release re: 2009 Financial Results
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 0pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibit&nbsp;99.2 Press Release re: Planned Public Offering
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>SIGNATURES</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dated: March&nbsp;3, 2010
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">GEOVAX LABS, INC.<BR><BR>

&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Mark W. Reynolds
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Mark W. Reynolds&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

</TABLE>

<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>g22351exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 99.1
</B>
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>

</TABLE>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="g22351g2235100.gif" alt="(GEOVAX LOGO)"></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:<BR><BR>

</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At The Company:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert McNally</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">678.384.7220 or <u>rmcnally@geovax.com</u></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At Financial Relations Board:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Leslie Loyet</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Relations</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.640.6672 or <u>lloyet@mww.com</u></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nikki Snodgrass</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Media Relations</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.640.6732 or <u>nsnodgrass@mww.com</u></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE<BR>
MONDAY, MARCH 1, 2010</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC. REPORTS FOURTH QUARTER AND<BR>
YEAR END 2009 FINANCIAL RESULTS</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><I>Submits Therapeutic Vaccine IND and Awaits FDA Response</I>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA, GA, March&nbsp;1, 2010 &#151; </B>GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology
company focused on development of HIV/AIDS vaccines, today announced its financial results for the
fourth quarter and year ended December&nbsp;31, 2009.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax reported a net loss of $843,285 for the fourth quarter ended December&nbsp;31, 2009, as compared
to a net loss of $1,039,217 for the comparable period in 2008. For the full year of 2009, the
Company reported a net loss of $3,284,252 as compared to a net loss of $3,728,187 in 2008. Grant
revenues were $3,668,195 and $2,910,170 for the years ended December&nbsp;31, 2009 and 2008,
respectively. As of December&nbsp;31, 2009, the Company reported cash balances totaling $3,515,784.
GeoVax&#146;s operating results fluctuate due to the timing of activities and related costs associated
with its vaccine research and development activities. Summarized financial information is
attached. Further information concerning the Company&#146;s financial position and results of operations
are included in its Annual Report on Form 10-K, expected to be filed with the Securities and
Exchange Commission on or before March&nbsp;12, 2010.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This past year we continued our work toward the advancement of clinical trials, as well as
increasing the awareness of our potential vaccine solutions for treating and preventing HIV/AIDS.
We are encouraged with our progress on both of these fronts,&#148; stated Robert T. McNally, Ph.D.,
president and chief executive officer. He continued, &#147;Our technology was further supported by the
September&nbsp;2009 success of a Thailand-based Phase 3 trial for an HIV/AIDS preventative vaccine
candidate owned by Sanofi-Aventis and Global Solutions for Infectious Disease, which for the first
time elicited both antibody and T cells. Our vaccine compares favorably in that it generates higher
frequencies of T cells and better quality antibody. We think that the GeoVax vaccine has the
potential to deliver a higher success rate than the 30&nbsp;percent achieved in the trial in Thailand.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;This disease has infected about one million people in this country alone and it&#146;s our aim to be
part of the solution. We have two vaccine clinical programs. One is for the prevention of the
disease for those who are not
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>GeoVax Labs, Inc.<BR>
Add 1</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">infected, whereas the second is a therapeutic, designed to help those already infected with
HIV-1. Both of our vaccines are based on the same technology and both have demonstrated encouraging
results in non-human primates,&#148; he continued.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Preventative Vaccine Trial &#151; Phase 2a</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company&#146;s preventative vaccine is in a Phase 2a trial, designated HVTN-205, that is being
conducted by the HIV Vaccine Trials Network (HVTN). The HVTN, funded by the NIH, is the largest
worldwide clinical trials network dedicated to the development and testing of HIV/AIDS vaccines.
Enrollment for this trial began in February&nbsp;2009. The trial will include a total of 225 volunteers
(150 vaccine recipients and 75 placebo recipients) and take place at 13 HVTN sites: 11 in North
America and two in South America.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Dr.&nbsp;Harriet Robinson, chief scientific officer and developer of the vaccine, stated, &#147;We are
currently enrolling in the HVTN Peru sites, which took longer to get fully enrolled than the U.S.
sites, due to the need for Peruvian review of the protocol. The trial is primarily a safety trial
and appears to be performing as expected.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Therapeutic Vaccine Trial &#151; IND Submitted to FDA</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The protocol for the Phase 1 clinical trial, conceived with collaboration from ARCA (AIDS Research
Consortium of Atlanta), will carefully monitor safety while evaluating the ability for the vaccine
to elicit protective immune responses in vaccinated participants. The proposed trial is based on
the achievement of excellent post vaccine viral control in animal studies conducted in recently
infected non-human primates at the Yerkes National Primate Research Center, affiliated with Emory
University.</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax completed a pre-Investigational New Drug (IND)&nbsp;meeting with the U.S. Food and Drug
Administration (FDA)&nbsp;for its therapeutic trial in December&nbsp;2009. The clinical path for this
non-blinded trial is expected to have a much shorter duration than the program for the development
of a preventative vaccine. The Company recently submitted its Investigational New Drug application
to the FDA for the therapeutic trial. Following receipt of the IND, the FDA has 30&nbsp;days to respond.
After that time, if there are no concerns from the FDA the Company may begin the trial.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Adding Resources to Support Growth</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are looking forward to continued progress in 2010. We moved to a larger facility in November
2009 to accommodate our expanding program and future anticipated higher levels of activity,&#148; stated
Dr.&nbsp;McNally. &#147;While we are adequately capitalized through 2010, thanks in part to $4.7&nbsp;million in
grant funding from the NIH during 2009, we are evaluating new funding opportunities to support our
growth,&#148; he added.</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About GeoVax Labs, Inc.</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and
commercialize human vaccines for diseases caused by HIV-1 and other infectious agents. GeoVax&#146;s
AIDS vaccine technology is the subject of 55 issued or filed patent applications in the U.S. and
other countries. GeoVax AIDS vaccines are designed for use in uninfected people to prevent
acquisition of HIV-1 and limit the progression to AIDS should a person become infected. GeoVax AIDS
vaccines also may be effective as a therapeutic treatment (for people already infected with the
HIV-1 virus).</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About HIV/AIDS</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation.
33&nbsp;million people are currently infected globally and it is estimated that there will be 2.5
million new infections this year. Since the beginning of the epidemic, over a million people in
the U.S. have contracted the virus. Every 9 <FONT style="font-size: 70%"><SUP>1</SUP></FONT>/<FONT style="font-size: 60%">2</FONT> minutes, someone in the U.S. is infected with AIDS.
Globally, HIV is the top killer among women of reproductive age.</DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>GeoVax Labs, Inc.<BR>

Add 2</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in
different regions of the world. Clade B is the predominant subtype in North America. Globally,
most infections involve subtypes AG, B, and C. In 2008, antiretroviral treatment in low and middle
income countries was restricted to about 3&nbsp;million people. In the United States, about 50% of those
who are infected are estimated to be on drug treatment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B><I>Safe Harbor Statement</I></B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>All statements in this news release, not statements of historical fact, are forward-looking
statements. These statements are based on expectations and assumptions on the date of this press
release and are subject to numerous risks and uncertainties which could cause actual results to
differ materially from those described in the forward-looking statements. Risks and uncertainties
include, but are not limited to, whether: GeoVax can develop and manufacture these vaccines with
the desired characteristics in a timely manner, GeoVax&#146;s vaccines will be safe for human use,
GeoVax&#146;s vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory
approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine
development, there is development of competitive products that may be more effective or easier to
use than GeoVax&#146;s products, and other factors over which GeoVax has no control. GeoVax assumes no
obligation to update these forward-looking statements, and does not intend to do so. Certain
matters discussed in this news release are forward-looking statements involving certain risks and
uncertainties including, without limitation, risks detailed in the Company&#146;s Securities and
Exchange Commission filings and reports.</I>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>FINANCIAL TABLES FOLLOW</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MORE</B>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>GeoVax Labs, Inc.<BR>

Add 3</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC.</B><BR>
<B>Statements of Operations Data</B><BR>
<I>(amounts in thousands, except per share data)</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="52%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Three Months Ended</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6">Year Ended</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000">December 31,</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="6" style="border-bottom: 0px solid #000000">December 31,</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
<TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">2008</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2">2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Grant Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">397</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">612</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,668</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,910</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Operating expenses:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:30px; text-indent:-15px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">538</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,016</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,068</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,741</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-15px">General and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">711</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">648</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,915</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,970</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,249</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,664</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,983</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,711</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Loss from operations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(852</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(1,052</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,315</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(3,801</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interest income</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(843</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(1,039</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,284</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(3,728</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Net loss per common share</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.00</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">$</TD>
    <TD align="right">(0.01</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="15" nowrap align="left" style="border-top: 3px double #000000">&nbsp;</TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD><DIV style="margin-left:15px; text-indent:-15px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Weighted averages shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">780,410</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">746,067</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">759,564</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">740,143</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>Balance Sheet Data</B><BR>
<I>(amounts in thousands)</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="76%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7" style="border-bottom: 1px solid #000000">December 31,</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000">2009</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="2" style="border-bottom: 0px solid #000000">2008</TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->

<TR style="font-size: 1px">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="7" align="left" style="border-top: 1px solid #000000">&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash and cash equivalents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">3,516</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left">$</TD>
    <TD align="right">2,191</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Working capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,309</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,455</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,316</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,056</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deficit accumulated during the development stage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(17,538</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left">&nbsp;</TD>
    <TD align="right">(14,254</TD>
    <TD nowrap>)</TD>
</TR>
<TR valign="bottom" style="background: #cceeff">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Total stockholders&#146; equity</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,744</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,710</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt">* * * * * * * * * * * * * * *
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">###
</DIV>









<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>g22351exv99w2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w2</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit 99.2</B>
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="35%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="25%">&nbsp;</TD>
</TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px"><IMG src="g22351g2235100.gif" alt="(GEOVAX LOGO)"></DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Contact:<BR><BR>

</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At The Company:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Robert McNally</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">678.384.7220 or <u>rmcnally@geovax.com</u></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">At Financial Relations Board:</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Leslie Loyet</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Relations</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.640.6672 or <u>lloyet@mww.com</u></TD>
</TR>
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Nikki Snodgrass</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Media Relations</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">312.640.6732 or <u>nsnodgrass@mww.com</u></TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>FOR IMMEDIATE RELEASE</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>MONDAY, MARCH 1, 2010</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>GEOVAX LABS, INC. PLANS PUBLIC OFFERING</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>ATLANTA &#151; March&nbsp;1, 2010 &#151; GeoVax Labs, Inc. (OTC BB: GOVX) </B>(the &#147;Company&#148;), an
Atlanta-based, biopharmaceutical company, today announced that it intends to file a registration
statement for the sale of $20.0&nbsp;million or more of its common stock. The offering may also include
shares to be sold by selling stockholders, although no arrangements have been made. The purpose of
the offering would be to raise funds to enable the Company to develop its vaccines business.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The Company anticipates filing the registration statement some time after it has filed its Annual
Report on Form 10-K for the year ended December&nbsp;31, 2009. The timing of the offering will be
determined at a later date, depending on several factors, including market conditions and when the
registration statement is eligible to be declared effective by the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release is being issued in accordance with Rule&nbsp;135 of the Securities Act of 1933, as
amended. THIS PRESS RELEASE IS NEITHER AN OFFER TO SELL NOR A SOLICITATION OF OFFERS TO PURCHASE
COMMON STOCK. A REGISTRATION STATEMENT RELATING TO THE COMMON STOCK OF THE COMPANY HAS NOT YET
BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION. THE OFFER, IF COMMENCED, WILL BE MADE ONLY
BY THE PROSPECTUS TO BE INCLUDED IN THE REGISTRATION STATEMENT
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Forward-Looking Statements</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><I>All statements in this press release, other than statements of historical fact, are
forward-looking statements. These statements are based on expectations and assumptions on the date
of this press release and are subject to numerous risks and uncertainties which could cause actual
results to differ materially from those described in the forward-looking statements. Risks and
uncertainties include, but are not limited to, whether the SEC will declare the proposed
registration statement to be effective and when, whether the Company will be able to sell its
common stock on terms acceptable to it or at all, market conditions, and factors over which GeoVax
has no control, including those described in the Company&#146;s most recent Annual Report on Form&nbsp;10-
K and its other SEC filings and reports. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so, unless otherwise required by law.</I></DIV>



<DIV align="center" style="font-size: 10pt; margin-top: 18pt">###
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g22351g2235100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g22351g2235100.gif
M1TE&.#EA$@$L`.8``-[@Z\/*W49:ELO3XK.ZTZ2LRF6"JXZ=P?K[_!0Q?MG>
MZ?'R]O3U^%MPI.?L\3-+C96BQ!(M?6M[JQ@U@863NB0\A9FDQ=#5Y*FRSHB5
MO"Q(BSM2DM38YEIKHHN:OKS%V%9GG4Q@FW*%L:JVT"E%BGR*M"1#B%1JH>'D
M[65[JW*"K^?I\<C.X+3"UB0_AK[+VWV7N+G`UA8S@)ZLR1X]A>[O]&%RI:2S
MS(.,M'6*LS12D.KL\IJIQ@XI=1`J>>3F[L;0WSY8E;>]U6ATJ!DT>^#B[&-V
MJ-7;YY6GQA(M>45AF3M2CL''V^_P]6!^I!DW@C9.CQPZA(>0MY&;P$UJGNWM
M\\C,WEEWI!XW@BQ"B'>%L=_?ZJFZSQ`K>_?X^N3I\)VGQU%FG]C<Z+&XT!,O
M?1`K=ALY@TUDFW^/MVIUHB9)BC98DD=GFZ2ZS3U@EQTY?BY0CR`^@28]@>3G
M[VAXJ6]_KD%>EZ^VT&N)KI"?P??W^K["V#!'BB`_AA$L?/___R'Y!```````
M+``````2`2P```?_@'^"@X2%AH>(B8J+C(V.CY"1DI.4E9:7F)F:DQQ!$1%/
M.@.;I*6FIZBIJI<@$5UD(0,,J[2UMK>XA5Y-*T4`O\#!P5L_.UZ.3"1=729W
MN<_0T=*'#@=#U]C783HF9%U^X.'BX5U/&F'9V1(W7X,%$7Y=&]/T]?:6+T@9
M^U0:6/]8)I`91["@P8/B$DP`*`.<&1T9.-R;2-'>C@$!`N0X$2($B88(R3V9
MT,=%!!<)9)A0]F3-%0-..H;H8,"`&PW@3)CQH\%D'QDD)GR+,"'!MZ)=H,@T
MD#'`J(I0HVI:4",&&BTG^GQ#2"9!@D\D=+"QXP**G0,M/EAH`6;&BQ<0_\!P
M>3'@PB`'`P:TN`$!PHL1$("T@-`""8P@&W0$`9G`Q"=XX\C0T*(E0(T:"Z1J
MWIQH1P$+4+8B9-:'A`DV>)!H07,#&HLGKTR(T)(CB`D3-+06)`-G2@S.P*$B
MX'#!1I8*7,G(Z+/&R4L@#E8XR#RM`;P(9U8(VA']@X$K#=RH2>D-7)<$6?B,
MX*`GN'MH#%*`2!"R2Q\U:GB\?5HQS+(^(RAR1``?7`'';3Z,(T,(*1#PWH.K
MY+$!%I`1=%YN(N0QP@(+(*`9!`UU\<`1C3#`X0=YI-`'#69L%8$,%4C``H0T
M8L+`!Q*<851!$200Q0DI6#!`$X6(0<"12"9YI/^'F``!`QIH'+`#(QO`(X,6
MDUQT0PH-R/!5.'PT4``*@S`AA!`*Q$!BC6SJ`H`-6(@VSHL::#`&D8840,<&
M<A(D0PV9B.$".!'0L<@,+?H1Q9J5+(`!&AKT`5D7$YS!0V8D$-$'%6MXT.:G
M?P3007D\FD%'!NT=@D(&(8D#:"8!P,,,$XIT$$\$*I#"@A%1P&9>!4)`0049
M:E`!:IM@5%#A.!,\(<$%LR`B!@FR)M!2`VC`H$(V+O10A29ZA.!-`G5$:X@"
M)/@1`0T!DL(`"R6<(-`W6)B`A`(_:'<LA`H8@9R%">C0``:+,!'$-V28T``%
M+[Q:R!U7F(O)`!.`TP?_F8?8`$\"2J32A`A03`"9`'M0M^][*VRP(T$)0#$C
M([:J*X,%SX0`S@1%())%/%%`L`H3=9@QD+H!G/P@&'V:-T$>CNQ!:!]"0(.&
M4'[\9@@&5),0-2T0F+'C!@H8'9P0,B2MZ!13-A+"=5!0@H`#OVR1=B(UH/!+
MSG^L\$`\-DC\QP\[^S&!`8*LL,4O**R`PN$H+(""+P#@3<@"D`/P`R)>6!`%
M?62@(39P(RP;3@("0)+%A4!,4H4-U,:C`1TT&\(`!5"4_0H=N7H@5`0.$E+$
MCC*P\($(+GQ#:1]]1-$%%C,\(-1Y*F`LB`5&14!&!HI,\00X6'S.&08&/6%U
M_R,90`8&DX_H00<6!;4<]B!"4$A0!#9,L3,L>`JB0C@9'&"&Z'[PT3<D\(,,
M``\,@P!#Q027`?0=`@'6B4`4QN<]J&``@#+0@40<P:H>%6(%*FA`!T9(P@[4
M@04(6(`'AB8#E=#@2WX(PLM&8()ED&$"02F;'V`A`*,\8(-_8`$?NB#!(`R*
MB&9@@]=<$8XH%$&%(''!'OZ0C)MYP&2)N(#()L"?"E8$?`4QU"-8I:Y"6.`@
M79`!`3X`DA\A809(R$$?O-$%(R"`8M](P`.0P`,D&&!>9&C%>;`D"#1P[H7P
MB,(&").',$2A0C3`FPN>)X$FU.$Z#W@$A5S@1:FP@/\&HB,7)"B@+AH0`@5J
M`*#2,&"S'ME@;G\8@\@H%8,S@J,!A6C`3G:XN0`.@D^46F`$@C`'0A#@`=>A
M`<84\`!OR(`&OB(!`!S!@B@D`7N=C$H#0"D.9MC%$10H&QD(,8<UO$$`Z$QG
M%EPQ`2UL8(=\<)@@$&`!H20@#SKX!A2L4`@&2,`;$7`>$27P!PL4KQP5BP`4
MI#<(%>Q.F8,`P.G$@2M',"`,21"`OK)9D1H806A;N9T\%0$&V$0`#=%J`@QZ
M1P@AQ&,"+'K%%`2A!PO4@0YT"(%1K@10GQT"E!&0`A2\(8`=O#.`&Q"GIPP!
MA#XD2`02RP/[P"$#@C:B"0W_2$`:*,A1BC"@`44AQP3HD*I%Z.$!"..G((YA
M"`"\%$$)V"`'9ID0E*0Q=H;H1@0.0`=XD(%LWW@"!IRYU$*PP*E^(!@A4@:9
M"G`5$0P0`1%`\*VN:N8(0:"!:'R0`RPFH@&$DL$BW$JI)US'&7^X0$&>$`3Z
M=`&OA6`B#CZP3E`8)0$YN,#VR'"`0S35!Q'(`%L%8825E0.(TC*"&G)@6>#,
M(0,:`,EY@C`#1EB!!N$X`:/:^M(4!,$/,@C",2Y`!CO@X;SG%4$`L.N'#2!7
M$!2H'@[^4%QQ9`$`'-CE!OSV!Q'0QP\0%00#Z!.!_YTG#`XDA!YRP`8D`"'!
MS97*_P(.(-`=TL`##EA$`6JXPWTB@K030`-8P6&#*B@`#D4S!`3`008;%$*B
MZNH#TSC`X0"60!"@!8<=-OJ'/6A@*`%&P1J6(8,P5&`9HGS@"U(7X?<@8`X2
M0HH>1]#%0LSA!*8%1P5L4(`N>[D`4W@I&H3PWP1T(`]H:(&:UTPB)I@@'E@0
M0`$(@($Z!,X/-LC,'/P3#QDH=@?*4E<(YER`#L2IB7A[`($[4`,(#*T"0"1`
M!X+0@DRLH,O2&$,!U%J12V-@I)&X0`R\6Y0)0"&WDB,$`)20KE91"@TU*(%I
MM_($&MCZUE#`T@S8ZQ"C$'$")N#T"**@+@%<3A`EF*JZ'O])J!TY40](`P<-
M'#0'&Y0'"AUH0`K"`((Q_.&K'9CB'R#0`!NDN!$L2$#W**&'(]!AA`W`YB.@
MD`1"/F(/'0`!!\!-JU*\(P%,.,(%(`P)/4")!E$HR@9X@(@">$F5Y$C`C?70
M@$>:S75%<S@3P[&N@14"E`E`0B'BNW%P6$NS`2P"&':TM$&L(`RN2(`9-$"!
M_"W`!`D@Z`Z"D(000`(("9!#)8[@5!IPHP.1V``9;@P)]H4``$UX0@\*8(IB
M3R$*9``U)9B@;0T\X0DG"``0AJN_$ZBA#W5*N]HU`(=OOEP-,U][VN$P33"$
MQP71I0$<MCN(`6@@"*D6Q`).H`/_E;C`!':@``2B4*<US%T)J2;`":Z0@FD:
M0@L)6,(?WM$##VA6!@=0``,"X%03Y.`#<%!.#FIR`QF\2`90*!H'4J`<"2!`
M""3P@0M8$"W5/J%=H8)"``,PX370@`PO><$/8``3F%#@"3[`>@G$H(<`N"`)
M$H`)D_]@@FOV-PI$R$`.KA"`%A@`#P30@0I($(<9Y`!&'/!""G;8!PYL(8`F
M>`((2%03)R@A`6S0?V(@!GA@`+`D"6)P!$C`!DJP!D%@!`I`#&LE!D7@`!9X
M@1CH`.CC!0J@`!F8@?FC.`XP@($W"&_#7X-0!$?P`RB@`%."`&+P@0YP@(Q0
M`F3P``N`_P5D4`<S<`9\T"LY50Y*X`9K4!1PX`8Z,`$](`6/1`,X1P87T'UR
M$`4]\`!8D`0,Z%Z"0%X21'5[X`)ED`4TT`,X@!Q]P`:.40`V2`00$`$]4`)>
MT@<U1`=U(`,XE``)$RT?X%05,"%^X`)!8`9+4`/E\P8%$$`BDP!PH!4Z<`14
M\`!\X`=$X%+*43%G4`-=\`8-,"A!8``I<0<20#ID=PD<H&8>P`97T`9M\#Y-
M1@A3(P<6T`5),&HG0`<?\14^4`!B,`9DX`-T4!<\,(92(`,](`%T$`\G$`%)
M``(5X`,=@%TB\#*"4`5A8!)F,`-5X@/BT@,A(`-)8`%%4"4]1/\$='`%$2`'
M$N`'/8`![\0'&I`$-A`#Q4,$[N`'27`<]'$&QZAY?"('XL(')Y``23`"K14$
MHB(!'7`>\^$"%%!<)\`J<:```E!O37`&2?`$9C!UI\``7[`"0+"*K5@(&;`Y
M#Y`$9R`!$S`!08`%3_!(]/@'36`&1$!UXT8&9*`%DL@$%D`&/3`>3W`;)J`"
M%!`%,L`'R+4"&*!H&F`"/J`2MQ%=9;`%?[!"7\$'8X"'%K`W;7,"/@!</K`%
M%U`\+B8([T`$`#`&3I4&9T`&FB<#/H`#-#`S8=8#?\"54``%BM@'"=`#3Y``
M1J`'4D`&8>`!74"/04`$GF,$:20##T#_@R&Y"DU0.T"Q!\IB`S:(0W[@`Q=P
M`59`!D%U`1Q0`A%`!"70!4*G!$6I!C*@`F>"$2Q``/;(-']``&&PF0+@C':0
M``W0F@(@B9?#`UYA!G50`P%4`'QP31>0*4N@@PC9(QOT`S^6!:'2BW=``F0`
M!2JP+A;0(V#@`1%0!BNP&&_`DQ@@`%T@`"5)!RB`!3[`!W#@`U"@/1,@`6+0
M`)XI`_/UF+GP3A%0-"+0$&[X`"S@`D.#!0>@6>?1(CW@"7SP!^OD`3/@>D2T
M`:!T'B103'^``;Z2`!H``&>P/6GD`6'@`R`@"&WH`R*P``I4!DK@`D3@`0'@
M!UAP`=W8(]_Y_TU%T!#>%J-O4`1]10:/I$=^4`92P`=DP`/E@P49T!`)0`.Z
M-P&^6`1*B)-DP`$H@$SM]4=DP$GZF0M@L`_MP0)(P`4\0`%VL0('\`%<8!<8
M\`(WX`'[@`('D`&`TIW\-`)(<``08`5(@`00@`3']@<<P`,W<`-(L"8Q<`!]
MQ`(WD`&*Q0(9L%1[D`$0$`,>@$"KD@=,D`$-4`)0$`%9H"\31@%B\`>K0@&8
M,0-Y``$'`*<94``+,`,9,`<!D`%,,P)<H*H>`*=3L`)-D`$4\`$'0`':00`O
M,`,_4%Q9\$U=VJR8@`$TX`(;\$@44`_LB!+,Y:S::@D[8`!!``5*P`UT]&"<
+&P!KVWJN'!4(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
